phohistiocytosis. Two genes located on chromosome 15q21 are associated with Griscelli syndrome: the myosin-Va and the RAB27A gene. 2, 3 Most patients can achieve temporary remission of the accelerated phases; 4 however, despite maintenance therapy, relapse usually occurs very early, often presenting as an infiltration of the central nervous system (CNS). The prognosis is poor, the average age for death being 5 years. 5 Stem cell transplantation is the only curative therapy and should be performed as soon as a remission is achieved in order to prevent relapse. To date, only four BMTs have been reported. 5, 6 We describe the first PBSCT with T cell depletion from the phenotypic HLA-identical mother in a 6-month-old girl with Griscelli syndrome.
Case report
The 22-year-old girl is the only child of healthy Armenian parents who are first cousins. After an uncomplicated pregnancy and delivery, the child developed a neonatal sepsis. Three months later two septic episodes occurred with fever, polyserositis and hepatosplenomegaly. The silvery hair (Figure 1 ) with the typical pigment clumps in the hair shaft and the hemophagocytosis in the bone marrow led to the diagnosis of Griscelli syndrome at the age of 3 months. 7 Genetic analysis showed a homozygote deletion 510AAGCC in the RAB27A gene.
According to the treatment of hemophagocytic lymphohistiocytosis reported by Stephan et al, 4 the patient received immunosuppressive therapy with prednisone (3 mg/kg/day) and rabbit antithymocyte globulins (10 mg/kg/day for 5 days). Complete remission was achieved within 1 week. MTX (2 × 6 mg) was administered intrathecally as prophylaxis against CNS infiltration. Remission was maintained by CYA 2 mg/kg/day i.v. until the transplant was carried out at the age of 6 months. Conditioning consisted of Bu 5 mg/kg p.o. in divided doses daily for 4 days (total dose 20 mg/kg), VP16 40 mg/kg i.v. 1 day and CY 60 mg/kg i.v. once daily on days 1 and 2 (total dose 120 mg/kg). Following G-CSF stimulation (12 g/kg/day) of the phenotypically HLA-identical mother for 5 days, white blood cells were collected by leukapheresis using a Cobe Spectra. Stem cell selection using the CliniMacs device (MiltenyiBiotec, Bergisch Gladbach, Germany) was achieved with magnetic beads coupled to anti-CD34 antibodies. 15.4 × 10 6 CD34-positive cells/kg and 17.6 × 10 3 CD3-positive cells/kg recipient weight were transfused to the patient. No GVHD prophylaxis was given because of the T cell depletion. To accelerate engraftment G-CSF (7 g/kg/day) i.v. was administered beginning on day +2. On day +12, WBC exceeded 1000/l. The last platelet transfusion was given on day +16.
The only side-effect was mild mucositis. Infections between day −4 and day +19 required several antibioticantimycotic treatment courses, but no microorganisms were detected. Grade I skin GVHD was treated with prednisone (2 mg/kg/day) beginning on day +12 for 2 weeks. No liver or gut GVHD occurred. The patient left hospital at day +44 in good condition.
Two months later, an EBV-induced lymphoproliferative syndrome complicated the course. Five perforations of the small intestine required surgery. After T cells had been obtained from the mother (1 × 10 6 CD3-positive T cells/kg recipient weight on day +95 and day +102) and CD20-antibodies against B-lymphocytes (Mabthera/Rituxan; Roche, Grenzach-Wyhlen, Germany, 375 mg/m 2 /dose on day +96 and day +103), the infiltration was halted. 8 Three months after the T cell therapy, GVHD of the whole skin occurred and was treated with high-dose steroids. As a side-effect of the antibody therapy, B-lymphocytes were not detected by FACS analysis in the peripheral blood for 7 months and immunoglobulin infusions are still necessary once a month.
Results
Twenty-six months after the transplant, the patient is in good condition with no signs of relapse. Her blood count is normal. Imaging shows no further infiltration of the abdominal organs with lymphohistiocytosis and there are no clinical signs of central nervous system disease. The initial, slow electroencephalogram curves have normalized and neurological development tests have shown no deficits. Chimerism studies carried out by polymerase chain reaction (PCR) on DNA-polymorphism show 52% donor cells in the peripheral blood (Figure 2 ).
Discussion
Severe infections in infants in association with hypopigmentation of the hair may indicate Griscelli syndrome, Chédiak-Higashi syndrome or Elejalde syndrome. Griscelli syndrome presents with large pigment aggregates in hair shafts of grey hair on light microscopy and the accumulation of mature melanosomes in the melanocytes of the skin. Chédiak-Higashi syndrome is characterized by giant melanosomes in the melanocytes and keratinocytes of the skin, and Elejalde syndrome by incomplete melanisation of the melanosomes in the melanocytes. 1, 5 In Elejalde syndrome, recurrent accelerated phases of the syndrome have not been reported. 9 Mutations on chromosome 15q21 in the myosin Va gene and in the RAB27A gene have been identified in Griscelli syndrome.
2,3,10 Myosin-Va and RAB27A are believed to participate in organelle transport 10, 11 and might explain the accumulation of melanosomes in the melanocytes in Griscelli syndrome.
In contrast to RAB27A, Myosin Va is detected in the brain 12 and mutations may be responsible for the primary neurological symptoms, 13 which are initially not present in patients with Griscelli syndrome, who have mutations in the RAB27A gene.
Only patients with a mutation in the RAB27A have an immunodeficiency and develop hemophagocytic lymphohistiocytosis. Mutations in RAB27A gene lead to decreased release of granule enzymes, such as perforin, in hematopoetic cells and thereby to a pathological reduction of the T and natural killer cell toxicity. 10 Lack of perforin-dependent cytotoxicity is an important factor in developing genetically determined hemophagocytic syndrome.
14 As a consequence of these data, stem cell transplantation should only be undertaken in Griscelli syndrome with evidence of a mutation in the RAB27A gene.
Remission of the accelerated phase can be achieved with chemotherapy or immunosuppressive therapy, but this is usually only of short duration. Infiltration of the central nervous system and other organs or severe infections lead to early death at the average age of 5 years. The only possibility of curing these patients is BMT. Transplantation has a better outcome if it is performed very early to avoid relapse, especially within the central nervous system. 5, 6 Approximately 40 patients with Griscelli syndrome have been reported to date. 5, 9 Despite immunosuppressive therapy, life expectancy without BMT is only 5 years. To date two out of four patients who received bone marrow transplantation are alive.
One patient received BMT from an HLA-identical sibling and was conditioned with Bu (16 mg/kg), VP16 (21 mg/kg) and CY (200 mg/kg). The patient is well 22 months after the transplant. 6 Klein et al 5 reported three patients who were transplanted from matched related donors. There is no information about the conditioning regimen. Five years after transplantation in 1989, one surviving patient is reported to be suffering from chronic GVHD and the other two died of severe infections.
The conditioning regimen for HLA-haploidentical transplants for immunodeficiencies normally includes only Bu and CY, but because hemophagocytic lymphohistiocytosis is an essential component of Griscelli syndrome with mutations in the RAB27A gene, we added VP16, which has been shown to be an active chemotherapeutic agent. 6, 15 The success rate for T cell-depleted HLA-mismatched transplants in severe combined immunodeficiencies is not significantly poorer than for HLA-matched transplants (57 vs 68%). 16 Patients with hemophagocytic lymphohistiocytosis who have received HLA-haploidentical transplants with T cell depletion face a 30% risk of failed engraftment. 17 To overcome this problem we gave large numbers of stem cells to our patient (15.4 × 10 6 CD34-positive cells/kg recipient weight). In general, the collection of large quantities of stem cells/kg recipient weight for HLAhaploidentical transplantation is not a problem. First, the patient's weight is generally very low because Griscelli syndrome is usually diagnosed in the first 12 months of life. Second, the HLA-haploidentical donors are usually adult and are as a rule a rich source of stem cells. Twentysix months after transplantation, the percentage of donor cells fell from 90% and has now stabilised at 52%. This probably demonstrates that a stronger conditioning regimen should be used in Griscelli syndrome or that the cell numbers transfused should exceed 20 × 10 6 CD34-positive cells/kg.
Conclusion
Transplantation should only be performed in patients with Griscelli syndrome who have a mutation of the RAB27A gene, since only these patients will develop immunodeficiencies and early lymphohistiocytic infiltrates.
Peripheral blood stem cell transplantation from a parent may be an alternative to transplantation from a matched unrelated donor. Due to the risk of early relapse of the lymphohistiocytic infiltrates, transplantation should be perforBone Marrow Transplantation med soon after remission is achieved. Valuable time can be saved with a parent acting as donor.
